XELJANZ/XELJANZ XR, THE FIRST ORAL JAK INHIBITOR IN THE U.S. FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS, IS NOW APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
A triple-drug focused remedy method may provide an efficient new treatment choice for power lymphocytic leukemia (CLL) that reduces the chance for the lengthy-time period unintended effects skilled with chemotherapy and is given for a restricted time, not as a day by day lifetime drug remedy.
New European research has found that a good social life could lower the risk of developing type 2 diabetes and pre-diabetes.
Over the past decade, the medical device industry has seen a boom in development and innovative ideas. With this innovation came a rise in the costs of medical device products which presents new challenges to buyers. With this in mind, we have compiled a list of 4 tips that could help you in this decision making process.
Cancer cells can lodge in different niches in the body, and the probe follows the spreading cells wherever they go
Pedro Pala, Clinical Trial Supply Manager, Bial, explores the implications of the new EU Clinical Trials Regulation
First of all, a 3D model of the patient was been created before surgery, combining images previously acquired via an MRI scanner, or radiography. On the day of the operation, a 3D image was (virtually) projected on the patient, and helped Dr Grégory in any of his movements and decision making.
The gene is in an area of the genome that does not contain instructions for making proteins. At one time, it was thought that this non-coding area was just irrelevant "junk."
Spark Therapeutics $ONCE has scored an historic FDA approval of Luxturna, the world’s first such AAV-delivered gene therapy designed to cure a rare eye disease triggered by a genetic mutation. The drug is OK’d for RPE65 mutation linked retinal dystrophy. The treatment uses a viral vector to insert the correct copy of a gene retinal cells need to create a protein that turns light into electric signals which can restore vision lost to the disease. As with the earlier pioneering approval of the world’s first CAR-T, FDA commissioner Scott Gottlieb did the honors in recognizing the importance of this approval. And he says the agency will make sure that the regulatory path is straight and clear for the rest of the field looking to following Spark’s footsteps. “We’re at a turning point when it comes to this novel form of therapy and at the FDA, we’re focused on establishing ...
“The sale of the PRV provides us with an important source of non-dilutive capital to help advance our pipeline of rare and ultra-rare therapies, and accelerates the availability of these potential therapies to patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.